Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
13
×
life sciences
national blog main
national top stories
13
×
boston blog main
boston top stories
new york blog main
new york top stories
biotech
san diego blog main
san diego top stories
san francisco blog main
clinical trials
san francisco top stories
boston
drugs
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alnylam pharmaceuticals
cancer
europe top stories
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
patisiran
tafamidis
What
medicine
13
×
fda
drug
approved
alnylam
gain
new
patients
big
bio
cancer
cells
friday
loss
making
momentum
nascent
oks
post
rna
rnai
roche
roundup
specifically
time
treatment
uses
vote
weight
acquire
afternoon
ago
agreed
alkermes
alnylam’s
announced
antipsychotic
approve
approves
atrophy
Language
unset
Current search:
fda
×
" national top stories "
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing